Sinphar Pharmaceutical CoTPE:1734 -0.15%80 Interest Coverage is 12.32 as of Dec. 2025, which is 49% above its 10-year median of 8.27. GuruFocus rates TPE:1734 with a GF Score™ of 80/100 and a GF Value™ of NT$33.14 (Fairly Valued). The stock has 1 warning sign investors should review. Among 377 Biotechnology companies, Sinphar Pharmaceutical Co ranks worse than 75.07% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Sinphar Pharmaceutical Co's
Operating Income
for the
three
months ended in Dec. 2025 was NT$96 Mil. Sinphar Pharmaceutical Co's Interest Expense for the
three
months ended in Dec. 2025 was NT$-8 Mil.
Sinphar Pharmaceutical Co's interest coverage for the quarter that ended in Dec. 2025 was 12.32.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Sinphar Pharmaceutical Co's Interest Coverage or its related term are showing as below:
TPE:1734'
s Interest Coverage Range Over the Past 10 Years
Min: 7.11 Med: 8.27 Max: 12.32
Current: 12.32
TPE:1734's Interest Coverage is ranked worse than 75.07% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs TPE:1734: 12.32
Sinphar Pharmaceutical Co (TPE:1734) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Sinphar Pharmaceutical Co Interest Coverage Related Terms
Sinphar Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TPE:1734 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's Interest Coverage falls into.
Sinphar Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a Interest Coverage of 12.32 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 49% above median its historical median of 8.27. Over the past decade, Sinphar Pharmaceutical Co's Interest Coverage has ranged from 7.11 to 12.32. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #283 out of 377 companies in the Biotechnology industry, placing it in the top 75.1%.
Is Sinphar Pharmaceutical Co's Interest Coverage too high?
Sinphar Pharmaceutical Co's current Interest Coverage of 12.32 is 49% above median its 10-year median of 8.27. Over the past 10 years, this metric has ranged from a low of 7.11 to a high of 12.32. The Biotechnology industry median Interest Coverage is 106.07. Sinphar Pharmaceutical Co's value of 12.32 is 88.4% below this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #283 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #283 out of 377 companies for Interest Coverage. This places Sinphar Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 106.07. Sinphar Pharmaceutical Co's value of 12.32 is 88.4% below this benchmark. Historically, Sinphar Pharmaceutical Co's own Interest Coverage has ranged from 7.11 to 12.32 over the past decade. While the company's 10-year median is 8.27 vs. the industry median of 106.07, Sinphar Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current Interest Coverage of 12.32 is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current Interest Coverage is 12.32, which is 49% above median its own 10-year median of 8.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$32.65 — trading 1.5% below its estimated fair value. The current Interest Coverage is 12.32, which is 49% above median its 10-year median of 8.27 and 88.4% below the Biotechnology industry median of 106.07. Sinphar Pharmaceutical Co's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Interest Coverage is 12.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$32.65 is trading 1.5% below its estimated GF Value™ of NT$33.14.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
Interest Coverage: 12.32 (49% above median its 10-year median of 8.27)
GF Value™: NT$33.14 vs. price of NT$32.65 (1.5% below fair value)
Industry Position: 88.4% below the Biotechnology median (#283 of 377)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
80GF Score
Get the complete analysis for TPE:1734
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
